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ABSTRACT  
Background: Palbociclib enhances endocrine therapy and improves clinical outcomes in hormone 
receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative metastatic breast 
cancer (MBC). As a new target, it is clinically important to understand palbociclib’s safety profile to 
effectively manage toxicity and optimize clinical benefit.  
Materials and Methods: Patients with endocrine-resistant, HR-positive/HER2-negative MBC (n=521) 
were randomly assigned 2:1 to receive fulvestrant (500 mg intramuscular injection) ± goserelin with 
either oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments at baseline 
and day 1 of each cycle included blood counts on day 15 for the first 2 cycles. Hematologic toxicity was 
assessed using laboratory data. 
Results: Patients (N=517: palbociclib, n=345; placebo, n=172) were treated; median follow-up was 8.9 
months. With palbociclib, neutropenia was the most common grade 3 (55%) and 4 (10%) AE; median 
time to onset and duration of grade ≥3 episodes was 16 and 7 days, respectively. Asian race and below 
median neutrophil counts at baseline were significantly associated with an increased chance of developing 
grade 3−4 neutropenia with palbociclib. Dose modifications for grade 3−4 neutropenia had no adverse 
affect on progression-free survival. In the palbociclib arm, febrile neutropenia occurred in 3 (<1%) 
patients. The percentage of grade 1−2 infections was higher compared with the placebo arm. Grade 1 
stomatitis occurred in 8% of patients. 
Conclusion: Palbociclib plus fulvestrant treatment was well tolerated and the primary toxicity of 
asymptomatic neutropenia was effectively managed by dose modification without apparent loss of 
efficacy.  
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Implications for Practice: Treatment with palbociclib in combination with fulvestrant was generally safe 
and well tolerated in patients with hormone receptor (HR)–positive metastatic breast cancer. Consistent 
with its proposed mechanism of action, palbociclib-related neutropenia differs in its clinical time course, 
patterns, and consequences from that seen with chemotherapy. Neutropenia can be effectively managed 
by a dose reduction, interruption, or cycle delay without compromising efficacy. A significant efficacy 
gain and a favorable safety profile support the consideration of palbociclib into the routine management 
of HR-positive/human epidermal growth factor receptor 2–negative metastatic breast cancer. 
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INTRODUCTION  
Endocrine therapy is the preferred first-line treatment option for hormone receptor (HR)–positive and 
human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) [1]. 
However, the fundamental clinical challenge associated with this treatment option is the development of 
resistance to endocrine therapy [2]. The mechanisms of resistance have yet to be fully elucidated [2]. 
Among women with disease progression following prior endocrine therapy, treatment options include 
sequential endocrine-based therapies, as monotherapy or in combination with a targeted therapy (eg, 
everolimus for some postmenopausal women), before switching to chemotherapy [1]. Clinical research 
has focused on enhancing and improving outcomes of endocrine-based therapy to augment disease 
control, delay the use of chemotherapy, and optimize the length and quality of life [1]. 
Palbociclib is a first-in-class potent oral inhibitor of cyclin-dependent kinases (CDK) 4/6 and a novel 
therapeutic option for the treatment of HR-positive/HER2-negative MBC [3].  In the endocrine-resistant 
setting, the recent global PALOMA-3 trial demonstrated the improved efficacy of palbociclib in 
combination with fulvestrant over fulvestrant plus placebo in pre-, peri- and postmenopausal women 
whose disease had progressed on prior endocrine therapy (median progression-free survival [PFS], 9.5 vs 
4.6 months; hazard ratio, 0.46 (95% CI, 0.36−0.59); p = .0001) [4]. The current data therefore suggest that 
palbociclib enhances endocrine therapy and improves clinical outcomes in both treatment-naive and 
endocrine-resistant patients with HR-positive/HER2-negative MBC [3,5]. 
Because palbociclib is incorporated into treatment paradigms for patients with HR-positive MBC, it is 
clinically important to understand its safety profile, both to effectively manage toxicity and to balance risk 
and benefit. With these goals in mind, a comprehensive safety analysis of patients enrolled in the 
PALOMA-3 study was undertaken, with particular emphasis given to neutropenia as the most frequently 
reported adverse event (AE) associated with palbociclib treatment. 
MATERIALS and METHODS  
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Patients  
Eligible patients had breast cancer and histologic or cytologic confirmation of recurrent local or distant 
disease progression during or within 12 months of completion of adjuvant endocrine therapy or while 
receiving or within 1 month after receiving endocrine therapy for MBC. Premenopausal and 
postmenopausal patients who had an Eastern Cooperative Oncology Group (ECOG) performance status 
0−1 and measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST, 
version 1.1 [6]) or bone-only disease with a lytic lesion were eligible. One prior line of chemotherapy in 
the advanced setting was allowed, but there was no limit on the number of prior of lines of endocrine 
therapy in the MBC setting. Eligibility criteria and study design details are documented elsewhere [5]. 
The protocol was approved by an institutional review board/independent ethics committee, and the study 
was conducted in accordance with the Declaration of Helsinki. All patients provided written informed 
consent before the start of any study procedures. 
Study Design 
The PALOMA-3 study (NCT01942135), a multicenter, randomized, double-blind, placebo-controlled, 
phase 3 trial, was designed to assess the superiority of palbociclib in combination with fulvestrant 
compared with placebo plus fulvestrant in prolonging PFS in women with HR-positive/HER2-negative 
MBC and disease progression after prior endocrine therapy. The primary endpoint is PFS and the 
secondary endpoints include a comparison of safety between treatment arms [5]. 
Treatment 
Patients were randomized (2:1) to receive palbociclib (125 mg per day, orally, 3 weeks on and 1 week 
off) plus fulvestrant (500 mg per month, intramuscularly, on days 1 and 15 of the first 28-day cycle and 
day 1 of subsequent cycles, ± goserelin per menopausal status; palbociclib arm) or placebo plus 
fulvestrant (placebo arm). If patients experienced a hematologic toxicity, such as grade 3−4 neutropenia, a 
specific dose modification schema consisting of dose interruption, dose delay, or dose reduction was 
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followed (Fig. 1). Dose modification for fulvestrant was not allowed. Primary prophylactic use of 
granulocyte-colony stimulating factors (G-CSFs) was not permitted [5]. If neutropenic complications 
were observed in a cycle in which primary prophylaxis with G-CSFs was not received, secondary 
prophylaxis was given at the discretion of the investigator, but only if dose modification was not 
considered a reasonable alternative. 
Safety Assessment  
Adverse events were assessed based on type, incidence, severity, timing, seriousness, and relatedness to 
study treatment. Severity was graded using the National Cancer Institute Common Terminology Criteria 
for Adverse Events version 4.0 [7]. Laboratory safety assessments were performed at baseline and on day 
1 of each cycle and included blood counts on day 15 for the first 2 cycles and at end of 
treatment/withdrawal. Additional blood tests were permitted at the investigator’s discretion as clinically 
indicated for the purpose of planning treatment, dose modification, or following AEs. 
Analysis 
Descriptive analysis was used to summarize the maximum grade AEs on treatment, using the Medical 
Dictionary for Regulatory Activities version 18.0 (MedDRA) terms. For hematologic toxicities, 
descriptive analyses of laboratory data were also performed when possible, because not all hematologic 
events may have been reported. The risk difference between the 2 treatment arms for hematologic events 
and nonhematologic events of interest was calculated, and the respective 95% CIs were also provided 
without adjustment for multiplicity. The AE incidence was based on the maximum toxicity grade during 
the treatment, as reported by investigators. Because many patients can have multiple episodes of an 
adverse hematologic event, and to further delineate the patterns of neutropenia, some of the analysis was 
per episode using the laboratory data in aggregate whereas the risk difference for hematologic events in 
both arms was considered using the proportion of patients with hematologic events in both arms. 
Exploratory analyses of PFS were conducted for different subgroups among the patients who received 
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palbociclib plus fulvestrant. The Kaplan-Meier (KM) method was used to estimate the median PFS and 
the 2-sided log-rank test was peformed for the PFS comparisons.  Hazard ratios and 2-sided 95% 
confidence intervals were estimated using Cox proportional hazards model. The KM method was also 
used to estimate the culmulative probability (ie, cumulative incidence function) of neutropenia and 
fatigue, separately.  
The relationship between baseline characteristics and grade 3−4 neutropenia was examined individually 
among patients in the palbociclib arm. Univariate analysis was used to assess the individual associations 
of these risk factors, which are presented as odds ratios with 95% CIs. A multivariate logistic model was 
run to evaluate the relationship between grade 3 and/or 4 neutropenia versus infection status, treatment, 
and key baseline factors (simultaneously considered in the model).  
RESULTS  
Patient Population 
Between October 7, 2013, and August 26, 2014, 521 patients were enrolled [5].  Two randomized patients 
per arm did not receive study treatment. The safety populations (as-treated) comprised 345 patients for the 
palbociclib arm and 172 patients for the placebo arm (Fig. S1). The safety data presented are from the 
March 16, 2015, cutoff with a median follow-up of 8.9 (interquartile range, 8.7−9.2) months for the 
intent-to-treat population. More than half (67%) of all patients had ≥2 disease sites, 35% of patients had 
≥2 lines of prior therapy in the MBC setting, and 34% of patients had undergone 1 line of prior 
chemotherapy in MBC setting.  
Overall Safety Profile  
For all cycles, the reported incidence of any grade and grade 3−4 AEs was 99% and 73%, respectively, in 
the palbociclib arm and 90% and 22% in the placebo arm. The risk difference for toxicities was higher for 
hematologic than for nonhematologic toxicities during the study (Fig. 2A). A significant difference 
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(>10%) in the incidence of the following treatment-emergent AEs of any cause (all grade) was reported in 
the palbociclib arm compared with the placebo arm: neutropenia, leukopenia, anemia, thrombocytopenia, 
stomatitis, alopecia, rash (all p < .005), infection, and fatigue (both p < .02). AEs of interest are shown in 
Fig. 2B. Most reported infections were upper respiratory tract infections of likely viral etiology. Fatigue 
in the palbociclib arm was commonly experienced (all grade, 39%), with 13% and 2% of patients 
experiencing grade 2 and 3 fatigue, respectively. The cumulative incidence of fatigue over time in the 
palbociclib arm is shown in Fig. S2. Among patients who had stomatitis or alopecia in the palbociclib 
arm, the severity was predominantly grade 1. Discontinuations due to AEs were similarly low in the 
palbociclib (4%) and the placebo (2%) arms (Fig. S1). In the palbociclib arm, treatment was discontinued 
for 1 patient each because of the following AEs: grade 4 neutropenia, grade 2 anemia, and grade 2 and 3 
thrombocytopenia. Four (1.2%) patients in the palbociclib arm and 3 (1.7%) patients in the placebo arm 
had grade 5 events (mainly related to disease progression) and after the data cutoff, one case of 
neutropenic sepsis and multiorgan failure in the context of disease progression was reported. 
The incidence of all-causality serious AEs (SAEs) was 44 (12.8%) of 345 patients in the palbociclib arm 
and 30 (17.4%) of 172 patients in the placebo arm. The most frequently reported type of SAE in the 
palbociclib arm was infections (2.0% vs 4.1% in the placebo arm), defined as any event that is part of the 
corresponding MedDRA System Organ Class. Besides infections, no other  SAE occurring on study up to 
28 days after the last dose of study drug reached an incidence of 2.0% in both arms: in the palbociclib 
arm, neutropenia and pyrexia were reported in 4 patients each and pulmonary embolism and pleural 
effusion were reported in 3 patients each; in the placebo arm, pleural effusion and ascites were reported in 
3 patients each. Results for SAEs occurring in >1 patient are shown in the supplement (Table S1). 
Thromboembolic events occurred in 2% of patients in the palbociclib arm (4 cases reported as SAEs and 
2 cases as AEs) and in no patients in the placebo arm. These events were not considered related to study 
drug by the investigator; however, the causal role of palbociclib cannot be completely excluded. 
Clinical Patterns of Neutropenia, Anemia, and Thrombocytopenia  
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In the palbociclib arm, grade 3 and 4 hematologic toxicities occurred for neutropenia (55.3% and 9.7%, 
respectively), leukopenia (41.5% and 1.2%), anemia (2.9% and 0%), and thrombocytopenia (2.1% and 
0.9%) per laboratory data. Among the patients who had grade 3‒4 neutropenia, only 3.2% had concurrent 
grade 3‒4 anemia and 3.2% had concurrent grade 3‒4 thrombocytopenia (Fig. S3).  
Median time from the first dose of palbociclib plus fulvestrant to the first appearance of a neutropenia 
episode of any grade was 15 (range, 13‒140) days, and the onset of the first episode of grade ≥3 
neutropenia was 16 (range, 13−293) days (Fig. 3A). The median time from the first dose to the lowest 
absolute neutrophil count (ANC) on study was 29 (range, 13−334) days. The median time from the first 
dose to the first occurrence of grade ≥3 anemia or thrombocytopenia was 39.5 and 26.5 days, 
respectively. The median duration of grade ≥3 episodes of neutropenia, anemia, and thrombocytopenia 
was 7.0 days for each event, with ranges of 1−98, 1−141, and 1−27 days, respectively (Fig. 3B).  
Among the 144 patients with a maximum of grade ≤2 (ie, grade 0, 1, and 2) neutropenia in the first 2 
cycles, 25 (17.4%) experienced grade 3 neutropenia beyond cycle 2, whereas 13 (9.8%) of 132 patients 
with a maximum of grade ≤2 neutropenia in the first 4 cycles experienced grade 3 neutropenia beyond 
cycle 4, and only 8 (6.3%) of 127 patients with a maximum of grade ≤2 neutropenia in the first 6 cycles 
experienced grade 3 neutropenia beyond cycle 6. None of the 132 or 127 patients in the palbociclib arm 
who experienced maximum grade ≤2 neutropenia within the first 4 or 6 cycles, respectively, developed 
grade 4 neutropenia in subsequent cycles.  
Univariate analysis revealed that Asian ethnicity and a below median value for ANC at baseline were 
patient characteristics that conferred a significantly increased risk for developing grade 3−4 neutropenia 
in the palbociclib arm. The percentage of Asian patients that developed grade 3−4 neutropenia was higher 
than for non-Asians (92% vs 57%; data not shown). Prior chemotherapy, age, ECOG performance status, 
and number of disease sites did not significantly increase the risk for developing grade 3−4 neutropenia 
(Table 1). 
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Clinical Outcomes of Neutropenia Associated With Palbociclib Treatment 
Although grade 3−4 neutropenia occurred in 221 (65%) of 340 patients in the palbociclib arm, febrile 
neutropenia was reported in only 3 (0.9%) of 345 patients in the palbociclib arm and 2 (0.6%) of 172 
patients in the placebo arm. During study treatment, 39 (11%) patients in the palbociclib arm received G-
CSF based on the investigator’s judgment.  
There was a higher incidence of all-grade infections in the palbociclib arm (42%) than in the placebo arm 
(30%); however, infections were mainly grade 1‒2 in severity; Fig. 2B. The frequency of grade 3‒4 
events was similar between treatment arms (2% and 3%, respectively). Fewer than 2% of patients in the 
palbociclib arm had concurrent grade 3‒4 neutropenia and grade 3‒4 infections. The multivariate analysis 
performed to assess the association between grade 3−4 neutropenia and infection showed that infection 
status was not significantly related to the presence of grade 3‒4 neutropenia (p = .17; Table S2) when 
treatment arm and important baseline characteristics were simultaneously considered in the analysis. 
Asian ethnicity and a lower median ANC at baseline were also found to be significantly associated with 
grade 3–4 neutropenia in multivariate analysis, which is consistent with the results from the univariate 
analysis.  
Assessment of Dose Modification Strategy and Effect on Efficacy  
The overall mean relative dose intensity was 86% for palbociclib plus fulvestrant and 100% for placebo 
plus fulvestrant (Fig. S4).  For the palbociclib arm, 28% of patients had 1 dose reduction (from 125 to 
100 mg or from 125 mg directly to 75 mg) and 6% of patients had 2 dose reductions (Fig. 4). The median 
time to the first dose reduction was 57.0 days (125 to 100 mg) and 36.0 days (125 to 75 mg and 125 mg 
directly to 75 mg [n = 8]), whereas for the second dose reduction the median time was 33.5 days (125 to 
100 mg for patients who had a dosing schedule change as a first dose reduction) and 119.5 days (100 to 
75 mg). Of the 117 (34%) patients in the palbociclib arm who received at least 1 dose reduction, 108 
(31%) were treated at the 100-mg dose level and 31 (9%) were treated at the 75-mg dose level. The 
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median duration of a dose interruption or dose delay in the palbociclib arm was 6.0 or 2.5 days, 
respectively. Among palbociclib-treated patients who had at least 1 dose reduction because of an AE 
versus those patients who had no dose reduction because of an AE, there was no effect on PFS (10.2 vs 
9.5 months, respectively; HR=0.74 [95% CI, 0.52−1.05)]; 2-sided log-rank test, p = .09; Fig. S5) 
Dose modification appeared to be effective at reducing the risk of subsequent grade 3‒4 neutropenia. 
Among the 21 (6%) patients who had a dose reduction owing to grade 4 neutropenia in cycles 1 and 2, 
only 1 patient developed subsequent grade 4 neutropenia. Among the patients (215 [62%] of 345) who 
developed grade 3−4 neutropenia in cycles 1 through 6, 56 (26%) had grade 3 neutropenia and 2 (0.9%) 
had grade 4 neutropenia subsequent to cycle 6. Although the number of repeated grade 3 events was 
reduced by half, it remained high because there was no mandated dose reduction for repeated grade 3 
neutropenia. A dose reduction due to uncomplicated grade 3 neutropenia was implemented if recovery to 
grade 2 neutropenia was protracted, or at the discretion of the investigator if uncomplicated grade 3 
neutropenia recurred in 2 consecutive cycles (Fig. 1). The KM plot estimates show that the cumulative 
incidence of grade 3‒4 neutropenia after receiving palbociclib plus fulvestrant increased early, 
predominantly in the first month, and subsequently plateaued (Fig. 5A). For patients who had mild to 
moderate neutropenia (grade ≤2) within the first 4 cycles of treatment, the risk of grade 3‒4 neutropenia 
was not substantially increased thereafter; it marginally increased over time up to 9 to 10 months, at 
which time it plateaued (Fig. 5B).  
Neutropenia and dose modifications due to neutropenia did not have a detrimental effect on efficacy 
among patients who had been treated with palbociclib plus fulvestrant for more than 3 cycles. There was 
no difference in PFS among patients who had grade ≥3 neutropenia versus grade ≤2 neutropenia (median 
PFS of 11.1 vs 11.0 months, respectively; HR=0.98 [95% CI, 0.64‒1.51]; 2-sided log-rank test, p = .93; 
Fig. 6A). PFS was not different among patients in the palbociclib arm who had at least 1 dose reduction 
because of neutropenia versus patients who had no dose reductions because of neutropenia (median PFS 
of 9.5 months each; HR=0.87 [95% CI, 0.61−1.25]; 2-sided log-rank test, p = .45; Fig. 6B). Among 
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palbociclib-treated patients who had a dose reduction, dose interruption, or cycle delay owing to 
neutropenia versus those who did not, there was no effect on PFS (median PFS of 9.5 vs 9.4 months; 
HR=0.85 [95% CI, 0.61‒1.18]; 2-sided log-rank test, p = .33; Fig. 6C). 
DISCUSSION  
The results of this global, randomized, placebo-controlled, phase 3 study in which palbociclib was 
combined with fulvestrant to treat patients whose HR-positive HER2-negative breast cancer had 
progressed on prior endocrine therapy confirmed the generally favorable safety profile that was also 
observed when palbociclib was combined with letrozole as first-line treatment for HR-positive/HER2-
negative MBC in a phase 2 study [3]. The AE incidence was similarly low for nonhematologic events 
across both treatment arms, and these AEs were mostly mild to moderate in severity. Although low grade 
stomatitis (apthous type ulcers which can bother patients) occurred more often in the palbociclib arm than 
the placebo arm, it can be effectively managed using steroid dental paste. The rate of thromboembolic 
events in the palbociclib and placebo arms was 2% and 0%, respectively. The 0.9% rate of pulmonary 
embolism in the palbociclib arm was consistent with recent data reported for pulmonary emboli in a 
similar patient population [8]. The overall SAE incidence was also low across both treatment arms. The 
hematologic AEs identified in the PALOMA-3 study were considered manageable and reversible and 
were not commonly associated with complications. The treatment discontinuation rate due to AEs was 
low (4%). This discontinuation rate is much lower than for other treatment options in this setting (ie, for 
inhibitors of the PI3K/mTOR pathways) that reached 19% in the BOLERO-2 trial[9] and 13% in the 
Belle-2 study[10]). The improved efficacy, coupled with the favorable safety profile of palbociclib plus 
fulvestrant, was also reflected in patient reported outcome data, which demonstrate patients were able to 
maintain quality of life during treatment whereas patients treated with placebo plus fulvestrant 
experienced a deterioration of their quality of life [11].  
13	
	
Although the most commonly observed grade 3−4 AE, neutropenia, occurred in more than 50% of 
patients, there was a low rate of associated febrile neutropenia. This observation confirms prior reports 
showing that the consequences of myelosuppression experienced during palbociclib treatment are 
different from those associated with chemotherapy-induced myeloablation [12], which is characterized by 
a more acute onset of neutropenia (observed clinically within 3 to 5 days) [13], and a prolonged 
suppression of all cell lines. This comprehensive safety analysis confirms that clinical time course, 
severity, and pattern of neutropenia are specific to the mechanism of action of palbociclib and do not 
appear to pose a significant safety risk for patients. In contrast to chemotherapy-induced neutropenia, the 
median time from first dose of palbociclib plus fulvestrant to first occurrence of grade ≥3 neutropenia, 
anemia, and thrombocytopenia was 16.0, 39.5, and 26.5 days, respectively. The median time from the 
first dose to the lowest ANC count was 29 days in the palbociclib arm. Reports in the literature show 
ANC nadirs postchemotherapy can range from 7 to 14 days[14]. Most importantly, the neutropenia 
associated with palbociclib treatment was effectively managed within days by dose delay, interruption, or 
reduction, without primary use of G-CSF, suggesting that mature white blood cells are present in the bone 
marrow, and can rapidly demarginate when drug levels fall.  
The clinical patterns of hematologic toxicities associated with palbociclib treatment are the mechanistic 
result of selective inhibition of CDK 4/6, which has been described in numerous other detailed reports of 
in vitro and preclinical in vivo experiments [12,15-17]. This mechanism of action is characterized by a 
blockage of the G1/S cell cycle transition to induce G1 arrest. Recent published data showed that 
palbociclib-induced bone marrow suppression follows cell cycle arrest in hematopoietic precursor cells, 
resulting in quiescence without apoptosis [12,15,16], whereas treatment with chemotherapy caused DNA 
damage and apoptoic cell death in human bone marrow mononuclear cells at clinically relevant 
concentrations [12,15,16]. Moreover, the short-term production of well-differentiated or mature 
peripheral blood effector cells (ie, mature neutrophils) was relatively resistant to CDK 4/6 inhibition. 
Myelosuppressive effects of CDK 4/6 inhibition were rapidly reversible in vivo. The destruction of 
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progenitor cells with subsequent development of neutropenia [18] is a major dose-limiting toxicity of 
chemotherapy [19]. Not only can it delay neutrophil recovery for several weeks, but it often leads to 
suboptimal treatment because of reduced dose intensity [20]. In contrast, the median duration of grade ≥3 
hematologic episodes in the current study was 7 days, suggesting that patients were generally able to 
resume treatment after 1 additional week off palbociclib treatment, and, as such, maintain the relative 
mean dose intensity. Chemotherapy-induced neutropenia is a well-known cause of complications, such as 
febrile neutropenia and infections, which may be life threatening [20,21]. In the PALOMA-3 study, 
febrile neutropenia occurred in 3 (0.9%) patients who received palbociclib plus fulvestrant treatment, a 
rate that was not markedly different from that observed in the PALOMA-1 study [3]. This confirms that 
febrile neutropenia is not commonly associated with palbociclib, likely owing to the shorter duration and 
lesser severity of neutropenia compared with chemotherapy [3].  
Preclinical data shows the cell cycle arrest caused by palbociclib plus fulvestrant is transient and 
reversible in hematopoietic cells [12]. However, cell cycle arrest was shown to minimally recover in the 
presence of fulvestrant alone during a palbociclib-free phase in breast cancer cells (MCF-7) [12]. The 
mechanistic difference between the effect of palbociclib on bone marrow versus MCF-7 breast cancer 
cells supports the current clinical dosing schedule and dose modification strategy by introducing short 
palbociclib-free periods to enable neutrophil recovery without affecting efficacy. This could also partially 
explain our finding that PFS was not affected by dose modification among patients who experienced 
grade ≥3 neutropenia compared with those who experienced grade ≤2 neutropenia. 
The data presented in this manuscript have important implications for clinical practice. There was no 
decrease in efficacy despite dose reductions, suggesting that patients maintained drug levels that were 
therapeutic during the study. Although many patients can be more susceptible to the myelosuppressive 
effects of palbociclib, our data suggest that the susceptibility to develop higher grade neutropenia during 
treatment can generally be recognized within the first several months of treatment and appropriately 
tailored dose modifications can be implemented to reduce the likelihood of recurrent episodes of severe 
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neutropenia and/or febrile neutropenia. Therefore, it is important to closely monitor ANC early during 
treatment with palbociclib so that dose adjustments can be made promptly in patients experiencing grade 
4 or prolonged and recurrent grade 3 neutropenia. This is particularly important for patients of Asian 
ethnicity and patients with a low baseline ANC. In PALOMA-3, patients had a complete blood count on 
day 15 for the first 2 cycles, and it is reasonable to consider this approach in clinical practice.  
The study showed that the incidence of all-grade infections was greater in the palbociclib arm than the 
placebo arm. Although the rate of grade ≥3 infections was similar between the palbociclib and placebo 
arms (2.0% and 2.9%, respectively), it is advisable to alert patients of the potential increased risk of 
infection.  
As with any targeted therapy, adherence to the recommended dose is critical to ensure treatment efficacy 
as well as safety in individual patients. Patients should be made aware of the palbociclib schedule, (3 
weeks on/1 week off). With close monitoring of the complete blood count, particularly early on during 
treatment, dosing can be optimized and ongoing treatment can be administered while minimizing the risk 
of clinically significant AEs. 
CONCLUSION 
Palbociclib has now been shown to be clinically effective in combination with 2 different endocrine 
agents in previously untreated and treated patients with HR-positive/HER2-negative MBC. A thorough 
understanding of the safety profile of this agent is a high priority consideration as clinicians incorporate 
this class of drug into their routine clinical practice. Treatment with palbociclib in combination with 
fulvestrant in the PALOMA-3 study was generally safe and well tolerated, with neutropenia representing 
the most common AE associated with its use. Clinical trial experience to date indicates a consistent and 
therefore predictable safety profile for palbociclib, with neutropenia being predominantly uncomplicated, 
and with a low associated risk of febrile neutropenia. Palbociclib-induced neutropenia is reversible and 
can be readily managed by dose delay, dose interruption, or dose modification without affecting efficacy. 
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The data presented here may also be informative for guiding ongoing trials  including adjuvant and neo-
adjuvant treatment settings.  
17	
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Figure Legends 
Figure 1. Palbociclib/placebo dose modification schema for managing treatment-related toxicities. aIf 
patients still have not returned to grade 2 on day 1 of next cycle. bReduce by 2 dose levels. cIf 
uncomplicated grade 3 neutropenia recurs in 2 consecutive cycles, after recovery as per retreatment 
criteria (ANC ≥1000/mm3 and no fever), treatment may restart at the next lower dose level at 
investigator’s discretion. dIf no further dose reduction is possible (ie, patient is already receiving 75 mg/d 
according to schedule 3/1), consider changing the schedule to 75 mg per day, 2 weeks on/2 weeks off, or 
discontinue palbociclib/placebo and continue with fulvestrant alone. 
Abbreviation: ANC, absolute neutrophil count. 
Figure 2. (A) Risk difference for AEs (hematologic lab and nonhematologic − all cycles, as treated) and 
(B) additional information on AEs of note. Percentages were calculated with respect to the total number 
of evaluable patients in a group (n), for which the denominators varied for laboratory measures. 
Hematology and chemistry laboratory results were graded according to the CTCAE severity grade. P 
values and CIs have not been adjusted for multiplicity. Palbociclib plus fulvestrant arm (n = 345); 
placebo plus fulvestrant arm (n = 172). aInfections includes any reported PTs that are part of the System 
Organ Class infections and infestations. bRash includes the following PTs: rash, rash maculo-papular, 
rash pruritic, rash erythematous, rash papular, dermatitis, dermatitis acneiform. cPulmonary embolism 
includes the following PTs: pulmonary embolism, pulmonary artery thrombosis. 
Abbreviations: AE, adverse events; CTCAE, Common Terminology Criteria for Adverse Events version 
4.0; Gr, grade(s); PT, preferred term.  
Figure 3. (A) Time to onset of hematologic toxicity in the palbociclib plus fulvestrant arm only and (B) 
duration of each episode by grade analysis based on laboratory data. Includes patients with postbaseline 
CTCAEs grade >0 and greater than baseline CTCAE grade. Percentages are based on number of episodes 
22	
	
in each subgroup. For multiple time to recovery periods within a patient, an average was calculated prior 
to summarizing among patients. 
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events. 
Figure 4. Exposure to palbociclib plus fulvestrant, time to onset for first and second dose reductions, time 
to dose interruption, and time to dose delay. aDue to adverse event. 
 
Figure 5.  Kaplan-Meier curves showing cumulative incidence of grade 3‒4 neutropenia.a,b (A) Patients 
treated with palbociclib plus fulvestrant. (B) Patients treated with palbociclib plus fulvestrant who had 
grade ≤2 neutropenia within the first 4 cycles and grade 3−4 neutropenia after cycle 4.  
aNeutropenia includes the following preferred terms: neutropenia, neutrophil count decreased. bThe 
Kaplan-Meier estimator was used to estimate the cumulative incidence in the plot. 
Abbreviation: Gr, Grade. 
Figure 6. Kaplan-Meier curves of progression-free survival in patients treated with palbociclib plus 
fulvestrant.  (A) Patients treated for more than 3 cycles who had maximum grade ≥3 (n = 186) vs 
maximum grade ≤2 neutropeniaa (n =93), per investigator assessment.  (B) Patients who had at least 1 
dose reduction because of neutropenia (n = 100)a versus no dose reduction (n = 245). (C) Patients who 
had a dose reduction, dose interruption or cycle delay due to neutropenia (n = 218)a versus the remaining 
patients (n = 127). aNeutropenia was any event having a preferred term equal to neutropenia or neutrophil 
decreased.  
Abbreviations: HR, hazard ratio; Gr, grade; max, maximum; NE, not estimable; PFS, progression-free 
survival. 
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TABLES	
	
Table 1. Risk of developing grade 3 or 4 neutropenia by clinical characteristics (odds ratio): as-treated 
 Palbociclib + fulvestrant (N = 345) 
 Grade 3−4 neutropeniaa   
Patient characteristics 
With, n (%) 
(n = 223) 
Without, n (%) 
(n = 122) Odds ratio p value 
Received prior chemotherapy, mo     
<12 50 (22.4) 24 (19.7)   
≥12 113 (50.7) 63 (51.6) 1.162 .61 
Immediately prior chemotherapy     
Yes  24 (10.8) 7 (5.7)   
No 199 (89.2) 115 (94.3) 1.981 .12 
Age, y     
<50  64 (28.7) 28 (23.0)   
50−70  128 (57.4) 75 (61.5) 1.339 .28 
≥70 31 (13.9) 19 (15.6) 1.401 .36 
ECOG performance status     
0 133 (59.6) 71 (58.2)   
1 90 (40.4) 51 (41.8) 1.062 .79 
Number of disease sites     
1 70 (31.4) 41 (33.6)   
2 62 (27.8) 33 (27.0) 0.909 .74 
≥3 91 (40.8) 48 (39.3) 0.901 .69 
Ethnicity     
Asian 67 (30.0) 6 (4.9)   
Non-Asian 156 (70.0) 116 (95.1) 8.303 <.0001 
Bone metastasis     
Yes 175 (78.5) 89 (73.0)   
No  48 (21.5) 33 (27.0) 1.352 .25 
Baseline ANCb     
≥ median value 86 (38.6) 94 (77.0)   
< median value 135 (60.5) 27 (22.1) 0.183 <.0001 
aNeutropenia included the following preferred terms: neutropenia, neutrophil count decreased. 
bANC median value in palbociclib + fulvestrant treatment arm was 3.6. 
Abbreviations: ANC, absolute neutrophil count; ECOG, Eastern Cooperative Oncology Group. 
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Figure S1. CONSORT diagram for the PALOMA-3 trial.  
(a) For reasons other than an adverse event. 
Figure S2. Kaplan-Meier failure plot of the cumulative incidence of all grades of fatigue for patients 
treated with palbociclib plus fulvestrant.  
Figure S3. Concurrent grade 3−4 hematologic events. Based on laboratory data. Neutropenia included 
laboratory tests of neutrophils (absolute/percentage). A neutropenia event was defined when the CTCAE 
grade for postbaseline tests of neutrophils (absolute) is >0 and >baseline CTCAE grade. Overlap 
percentages are based on the subgroup of patients in the palbociclib plus fulvestrant arm with grade 3−4 
neutropenia, n = 221. Neutropenia included the following preferred terms: neutropenia, neutrophil count 
decreased. 
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events version 4.0.  
Figure S4. Mean relative dose intensities for treatment arms by cycle number. Dose intensity was defined 
as the actual dose intensity divided by the intended dose intensity multiplied by 100%. 
Figure S5.  Kaplan-Meier plot of patients in the palbociclib plus fulvestrant arm who had at least 1 dose 
reduction because of adverse events (n = 114) vs no dose reduction (n = 231).  
Abbreviation: NE, not estimable. 
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